triumph-3 retatrutide #obesity #osteoarthritis #clinicaltrials #medicine #research A summary slide of the

These are game-changing medications, says Shauna Levy, M.D., an obesity medicine physician at the Tulane University Medical Center in New Orleans and the medical director of Tulanes Bariatric and Weight Loss Center

These medications are not recommended in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Two medications have reshaped the weight loss conversation in recent years: Contrave, a combination of naltrexone and bupropion, and Ozempic (semaglutide), a GLP-1 receptor agonist that mimics a natural hormone regulating appetite and blood sugar

They work through completely different metabolic pathways in the body

However, studies indicate that GLP-1 users consume 20% to 30% less energy, and the impact is particularly pronounced in junk food and other high-calorie foods